Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹64 Cr
verification pending
Revenue YoY
10%
reported change
EBITDA
₹11 Cr
latest reported figure
Source
manual review required
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Jagsonpal Pharmaceuticals reported a strong Q4 FY26 recovery with revenue of ₹64 crore (+10% YoY) and PAT of ₹9 crore (+31% YoY), driven by improved MR productivity and sharper brand focus in gynecology and dermatology. The company outperformed the IPM with 14.2% growth in Q4 (vs IPM ~10.5%) and 12.2% MAT growth (vs IPM ~8.6%). Management reiterated its target of growing at 1.5x IPM (implying 12-15% revenue growth) and expects margin stability. A ₹40 crore buyback and 200% dividend (including 75% special) underscore capital discipline. Key risk: cost pressures from Middle East disruptions on packaging and raw materials, though management believes impact on profitability will be limited.
Colored figures show movement against the previous available record.
Guidance to track
- Management targets growing at 1.5 times the Indian Pharma Market growth, implying 12-15% revenue growth based on current IPM trends.
- Plans to launch 9-10 new products or brand extensions in FY27, with half being brand extensions and half new products in core therapies.
- Management stated they do not intend to increase MR numbers, with growth driven entirely by productivity improvements.
Risks flagged
- Packaging material costs are rising due to Middle East tensions, and CMO partners may pass on cost increases, though management expects limited profitability impact.
- Management acknowledged that new product establishment takes over a year for prescription pickup, and some products may not achieve expected market traction.
- Top 10 brands constitute 58-60% of sales; any slowdown in these brands could materially impact overall growth, though management sees balanced portfolio.
Key quotes
- We have done the walk the talk. We have given you a guidance that we'll be looking at beating the market growth and that is what our objective has been.
- We are certainly targeting 1.5x of the pharma industry growth. Currently the pharma industry is trending anywhere between 6-7% to 8-9%.
- We are not adding any new MR. But we are trying to see whether organically from the same geography we are able to extract more and thereby conserving our cost as well.
Research modules